Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
08:00am, Wednesday, 16'th Apr 2025
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F.
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Thursday, 27'th Mar 2025
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the
Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript
06:25pm, Thursday, 20'th Mar 2025
Vaxart, Inc. (NASDAQ:VXRT ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Ed Berg - SVP and General Counsel Steven Lo - CEO James Cummings - CMO Sean Tucker - Founder
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
06:15pm, Thursday, 20'th Mar 2025
VAXART, INC. (VXRT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10.
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
04:01pm, Thursday, 20'th Mar 2025
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
08:00am, Tuesday, 11'th Mar 2025
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose
Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart's oral vaccine platform in generating mucosal antibody responses beyond the sit
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
07:55pm, Monday, 13'th Jan 2025
Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
04:01pm, Monday, 02'nd Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxar
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
06:20pm, Wednesday, 13'th Nov 2024
VAXART, INC. (VXRT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10.
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
06:19pm, Wednesday, 13'th Nov 2024
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Offic
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
04:01pm, Wednesday, 13'th Nov 2024
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinica
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
04:12pm, Monday, 30'th Sep 2024
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine com
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 30'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of th
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
01:57pm, Thursday, 15'th Aug 2024
Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
